Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD
Authors:
- 30 July 2021
- journal article
- research article
- Published by Springer Nature in Molecular Psychiatry
- Vol. 26 (12) , 7465-7474
Abstract
Anxiety and depression have been suggested to increase the risk for post-traumatic stress disorders (PTSD). A link between all these mental illnesses, inflammation and oxidative stress is also well established. Recent behavior studies by our group clearly demonstrate a powerful anxiolytic and antidepressant-like effects of a novel growth hormone releasing hormone (GHRH) antagonist of MIAMI class, MIA-690, probably related to modulatory effects on the inflammatory and oxidative status. In the present work we investigated the potential beneficial effects of MIA-602, another recently developed GHRH antagonist, in mood disorders, as anxiety and depression, and the possible brain pathways involved in its protective activity, in adult mice. MIA-602 exhibited antinflammatory and antioxidant effects in ex vivo and in vivo experimental models, inducing anxiolytic and antidepressant-like behavior in mice subcutaneously treated for 4 weeks. The beneficial effect of MIA-602 on inflammatory and oxidative status and synaptogenesis resulting in anxiolytic and antidepressant-like effects could be related by increases of nuclear factor erythroid 2-related factor 2 (Nrf2) and of brain-derived neurotrophic factor (BDNF) signaling pathways in the hippocampus and prefrontal cortex. These results strongly suggest that GHRH analogs should be tried clinically for the treatment of mood disorders including PTSD.Keywords
Funding Information
- Università degli Studi G. d'Annunzio Chieti - Pescara (FAR 2020 (to Lucia Recinella and Sheila Leone))
This publication has 70 references indexed in Scilit:
- Increased peripheral NF-κB pathway activity in women with childhood abuse-related posttraumatic stress disorderBrain, Behavior, and Immunity, 2012
- BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidityMolecular Psychiatry, 2011
- A Role for Central Nervous Growth Hormone-Releasing Hormone Signaling in the Consolidation of Declarative MemoriesPLOS ONE, 2011
- Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in miceProceedings of the National Academy of Sciences, 2010
- A Meta-Analysis of Cytokines in Major DepressionBiological Psychiatry, 2010
- Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-AnalysisPsychosomatic Medicine, 2009
- Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer lineProceedings of the National Academy of Sciences, 2008
- Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: Behavioral and neurophysiological evidenceNeuroscience, 2008
- Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001